Objective: CD4 + latency-associated peptide (LAP) + regulatory T cells (Tregs) are a newly discovered T cell subset in humans and the role of these cells in patients with acute coronary syndrome (ACS) has not been explored. We designed to investigate whether circulating frequency and function of CD4 + LAP + Tregs are defective in ACS.
Introduction
Atherosclerosis is a chronic inflammatory disease involving immunologic imbalance. Various immune cells, macrophagocyte, monocyte, lymphocyte especially T lymphocytes participate in the chronic inflammatory reaction and ultimately lead to the occurrence and development of acute coronary syndrome (ACS) [1] [2] [3] [4] . Regulatory T cells (Tregs) play an important role in maintaining peripheral tolerance, preventing autoimmune diseases, and restraining chronic inflammatory diseases [5] [6] [7] [8] . Previous studies have shown that naturally occurring CD4 + CD25 + Tregs are down-regulated in patients with acute coronary syndrome (ACS) [9] [10] [11] .
The classical Treg phenotype is defined as CD4
T cells [12] [13] . Recently, Weiner laboratory identified a novel population of human Tregs in peripheral blood that were characterized by the expression of latency-associated peptide (LAP) [14] . LAP is a linker pro-peptide that is specific for the active form of transforming growth factor-b (TGF-b) [15] [16] [17] . TGF-b is secreted as a latent complex in which the N-terminal region is non-covalently associated with LAP, while the C-terminal homodimer corresponds to mature TGF-b. In order for latent TGF-b to become active, the mature TGF-b must be released from LAP [16] [17] [18] . The CD4 + LAP + T cells lack Foxp3 expression, but they function similarly to the classical CD4
FOXP3
+ Tregs and produce a suppressive effect on immune response. In vitro, the suppressive activity of CD4 + LAP + T cells is dependent on TGF-b, interleukin-10 (IL-10), and cell-cell contact [14] . CD4 + LAP + T cells have been shown to suppress murine autoimmunity in experimental models of encephalomyelitis, systemic lupus erythematosus, colitis, and diabetes [24] [25] [26] [27] [28] [29] [30] . Glycoprotein A repetitions predominant (GARP), an 80-kDa type I transmembrane glycoprotein leucine rich repeat (LRR), is highly expressed in activated Tregs [19] [20] [21] . GARP binds directly to LAP and tethers latent TGF-b on the surface of activated Tregs, and it has been clarified that GARP is a receptor for latent TGF-b [22] [23] .
The role of this novel subset of Tregs has been studied in many diseases, including systemic lupus erythematosus, experimental autoimmune encephalomyelitis, diabetes, and atherosclerosis [24] [25] [26] [27] [28] [29] [30] [31] 
Materials and Methods

Patients
Two hundred twenty-eight patients from Wuhan Union Hospital were classified into three groups: (1) acute coronary syndrome (ACS) group(including acute myocardial infarction (AMI) and unstable angina (UA), 111 patients in total; 64 men and 47 women; mean age, 5967 years; inclusion criteria: acute myocardial infarction confirmed by significant rise of creatine kinase-MB and troponin I levels and/or not ST segment elevation, and unstable angina confirmed by chest pain at rest with definite ischemic proof, including ST-segment changes and/or T-wave inversion and angiographic evidence of coronary artery stenosis (.70%)); (2) chronic stable angina (CSA) group (29 men and 21 women, mean age 5869, inclusion criteria: effort angina (lasting .3 months and without a previous history of unstable angina or myocardial infarction and angiographic evidence of coronary artery stenosis (.70%)); and (3) the chest pain syndrome (CPS) group (35 men and 32 women, mean age 5766, inclusion criteria: chest pain not accompanied by electrocardiographic changes, coronary artery stenosis (Coronary angiography or coronary CTA), or coronary spasm [32] ). The exclusion criteria included the following: (1) patients treated with anti-inflammatory drugs such as non-steroidal anti-inflammatory drugs and steroids; (2) those who have diseases including connective tissue disease, thromboembolism, disseminated intravascular coagulation, advanced liver disease, renal failure, malignant disease, or other inflammatory disease (such as septicemia or pneumonia); (3) those who have other heart disease such as rheumatic heart disease, valvular heart disease or congenital heart disease, or atrial fibrillation or those using a pacemaker.
Ethics statement
The investigation conforms to the principles outlined in the Declaration of Helsinki. The trial was approved by the ethics committee of Tongji Medical College of Huazhong University of Science and Technology. Patients and controls provided written informed consent.
Sample preparation and peripheral blood mononuclear cell (PBMC) isolation
Blood samples were obtained from all the patients within 24 hours after admission. PBMCs were isolated by Ficoll density gradient centrifugation and were used for flow cytometric analysis and FACS sort and cell culture and real time-polymerase chain reaction (RT-PCR). Serum was collected after centrifugation, aliquoted, and frozen at 280uC for subsequent determination of cytokine expression.
Flow cytometric analyses
PBMCs were stained with anti-human CD4-FITC (R&D Systems) and anti-human LAP-PE (clone 27232, R&D Systems) for 30 min at 4uC. Anti-mouse IgG1-PE (R&D Systems) isotype controls were used to enable normalization and confirm antibody specificity. Antibodies were used without dilution. Stained cells were analyzed by flow cytometry using a FACS Calibur machine (BD).
PBMCs were resuspended at a density of 2610 6 cells/ml in RPMI 1640 (ATCC modification A1049101 Gibco) supplemented with 10% heat-inactivated fetal calf serum(Gibco), 10% nonessential amino acids solution (Gibco), 100 U/ml penicillin, and 100 U/ml streptomycin. The cell suspension was seeded in 24-well culture plates. Cells were stimulated by exposure to soluble anti-CD3 (eBioscience, 5 mg/ml) and anti-CD28 (eBioscience, 2 mg/ml each) for 24 hours. The incubator was set at 37uC under a 5% CO 2 environment. After 24 hours, the cells were harvested and stained with anti-human LAP-APC (clone 27232, R&D Systems), anti-human CD4-FITC (R&D Systems), and anti-human GARP-PE (G14D9, eBioscience) for 30 min at 4uC. Antibodies were used 
Proliferation and suppression assays
PBMCs were stained with anti-human CD4-FITC (R&D Systems), anti-human-LAP-PE (R&D Systems), and anti-human CD25-PerCP (Biolegend) for 30 min at 4uC. Antibodies were used without dilution. After the surface staining, the responder T cells ( Tresps from controls (CPS and CSA patients) at a 1:1 ratio,
Tregs from controls were co-cultured with CD4 + LAP 2 CD25 int/low Tresps from ACS patients at a 1:1 ratio. T cells were incubated in complete RPMI 1640 (ATCC modification A1049101 Gibco) supplemented with 10% heatinactivated fetal calf serum (Gibco), 10% non-essential amino acids solution (Gibco), 100 U/ml penicillin, and 100 U/ml streptomycin at 37uC with plate-bound (5 mg/ml, eBioscience) anti-CD3 and soluble anti-CD28 (2 mg/ml, eBioscience) in 5% CO 2 for 72 h in U-bottom 96-well plates. Antibodies were used without dilution. All cells were cultured in a final volume of 200 ml. 
Real-time PCR
RNA was extracted from freshly isolated PBMCs and CD3/28-sitmulated PBMCs (as described above) with RNAiso Plus (Takara Biotechnology) and reverse transcribed to cDNA using a RNA PCR Kit (Takara), according to the manufacturer's instructions. Expression of target genes was quantified using the SYBR Green Master Mix (Takara) on an ABI Prism 7900 Sequence Detection system (Applied Biosystems). All reactions were performed in at least duplicate for each sample. Primer pairs were as follows:
GARP: Forward: 59-CCCTGTAAGATGGTGGACAAGAA-39;
Reverse: 59-CAGATAGATCAAGGGTCTCAGTGTCT-39 b-actin: Forward:59-TCGTCCACCGCAAATGCTTCTAG-39
Reverse: 59-ACTGCTGTCACCTTCACCGTTCC-39 Relative mRNA expression levels were calculated using the comparative CT methodformula 2-DDCT . Data were normalized to b-actin [33] .
Cytokines detection
The plasma levels of TGF-b1 and IL-10 were measured by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (both from R&D Systems). The detection limits were 4.61 pg/mL for TGF-b1 and 3.9 pg/ml for IL-10. The intra-assay and inter-assay variation coefficients for all ELISA were ,10%. All samples were measured in duplicate.
Statistical analyses
Data are expressed as the mean6SEM in the figures. Differences were evaluated using one-way ANOVA for multiple comparisons, followed by a post hoc Student-Newmann-Keuls test and multivariate analysis when necessary. For the ranked data, Pearson's X 2 test or Fisher's exact test was performed for the comparison between groups. All analyses were conducted using SPSS (Statistical Package for the Social Sciences) 17.0 software, and statistical significance was set at p,0.05. 
Results
Basic clinical characteristics of the study population are summarized in Table 1 . There were no significant differences in age, gender, diabetes mellitus status, hypercholesterolemic status, or the use of aspirin or calcium blockers, or smoking status among the patients with ACS, CSA, or CPS groups. There were significant differences in hypertension and the use of clopidogrel, b-blockers, statins, angiotensin-converting enzyme inhibitors Tregs expression use multivariate analysis, moreover, as shown previously, the circulating CD4 + LAP + Tregs levels were also not correlated with hypertension (data not shown) [48] .
The frequency of circulating CD4
+ LAP
+ Tregs is decreased in patients with ACS
We determined the frequency of circulating CD4 + LAP + Tregs using flow cytometry. We found that the percentage of circulating 
The frequency of circulating CD4
+ GARP + T cells and
cells is decreased in patients with ACS
GARP is reportedly a receptor of LAP. We therefore measured the expression of GARP on CD4 + T cells. As GARP is highly expressed on activated T cells, we first stimulated PBMCs with 
GARP mRNA expression decreased in patients with ACS
We measured the expression GARP mRNA by RT-PCR with freshly isolated PBMCs and CD3/28-sitmulated PBMCs. In stimulated PBMCs, the expression of GARP was decreased in ACS patients (0.6960.09) compared with CSA (1.160.13) and CPS (1.1360.13) groups (*p,0.05; Figure 6A ). In unstimulated PBMCs, the expression of GARP was also decreased significantly in ACS patients (0.7560.10) compared with CSA (1.1260.11) and CPS (1.2360.15) groups (*p,0.05) ( Figure 6B ). There was no difference in GARP expression in cells from CPS and CSA patients.
Serum levels of TGF-b1decreased in patients with ACS
TGF-b1 and IL-10 are the main effector cytokines of not only classic Tregs, but also CD4 + LAP + Tregs [14, 36] . As shown in Figure 7 , TGF-b1 levels were reduced in patients with ACS (11.9360.67 ng/ml) compared with CSA (15.561.15 ng/ml) and CPS (16.7861.19 ng/ml) patients (p,0.05). There was no difference between CPS and CSA patients (p = 0.45). In contrast, there was no difference in IL-10 levels among the three groups (ACS, 27.3961.37 pg/ml; CSA, 29.361.44 pg/ml; and CPS, 28.7561.51 pg/ml) (p.0.05).
Discussion
Due to the observation that regulatory T cells are associated with suppression of inflammation, many studies have attempted to elucidate the role of Tregs in inflammatory diseases [35] [36] [37] [38] [39] . Previous animal studies have demonstrated that enhancements in the numbers of circulating Tregs can alleviate the progression and severity of encephalomyelitis, systemic lupus erythematosus, colitis, diabetes, and heart failure [40] [41] [42] [43] . Consistent with this purported function, it has been previously shown that acute coronary syndrome (ACS), a chronic inflammatory disease [1] [2] [3] [4] , is associated with a reduction in the number and function of circulating ''classical'' CD4 + CD25 + FOXP3 + Tregs [9] [10] [11] [44] [45] [46] . Since inflammation is known to be a significant contributor to the pathogenesis of cardiovascular disease, we studied the number and function of a novel subset of regulatory T cells, termed CD4
+ LAP + Tregs, in patients with ACS. This subset of Tregs is stimulated by production of TGF-b and IL-10 and is known to possess potent anti-inflammatory activity (14) . We hypothesized that the number and function of CD4 + LAP + Tregs would be reduced in patients with ACS compared to control patients (CSA and CPS).
We isolated CD4 + LAP + Tregs from PBMCs harvested from patients with AMI and UA (the ACS groups), and compared the number of Tregs to those of patients with CSA or CPS (control groups). The frequency of circulating CD4 + LAP + Tregs was significantly reduced in patients with ACS compared to frequencies in patients in the control groups. Furthermore, CD4
Tregs functions of suppressing responder T cells from ACS patients were compromised as demonstrated by analyses of proliferation. These findings are similar to those reported by Cheng et al. [9] [10] [11] and other researchers [44] [45] [46] .
Recent studies suggest that membrane glycoprotein A repetitions predominant (GARP or LRRC32) is a receptor for LAP on the surface of activated human Tregs [22] [23] . This provided the rationale for us to examine whether the expression of GARP was altered. As expected, we found that the expression of GARP on CD4 + T cells was down-regulated in patients with ACS. We also found that percentages of CD4
+ T cells were reduced in ACS patients compared with controls. GARP can regulate the bioavailability and activation of TGF-b by directly combined with LAP [22, 23, 47] . Thus, we conclude that GARP down-regulation is correlated with the defection of CD4 + LAP + Tregs. Additional studies are warranted to further evaluate the role of GARP in the pathogenesis of ACS.
Like CD4
+ Tregs, the suppressive activity of CD4 + LAP + Tregs has been shown to be dependent on both TGFb1 and IL-10 in vitro [14, 34] . We found that serum TGF-b1 levels were reduced in ACS patients compared with those of CSA and CPS patients, but we failed to detect a significant difference in IL-10 levels. Since, CD4 + LAP + Tregs secrete an array of cytokines, including IL-8, IL-9, IL-10, IFN-c, and TGF-b [14] , the finding that TGF-b1 levels are reduced may suggest a decrease in function and number of circulating CD4 + LAP + Tregs in patients with ACS. Previous studies have shown that TGF-b can induce surface LAP expression on murine CD4 + T Cells [48] , therefore, reduced TGFb1 levels may account for the lower LAP expression on CD4 + T cells, and lead to the down-regulated frequency of CD4 + LAP + Tregs in patients with ACS. Since ACS patients feature higher systemic levels of inflammation, including CRP, TNF-a, IL-6, but lower levels of TGF-b1 [49] , CD4 + LAP + Tregs may be involved in the progression of ACS.
In conclusion, this study is the first to demonstrate that the frequency of circulating CD4
+ LAP + Tregs is reduced and their suppressive function compromised in patients with ACS. A possible mechanism for this effect may be related to the downregulation of GARP and lower levels of TGF-b1. Yamamoto group demonstrated that local injection of LAP inhibits dermal sclerosis in bleomycin-induced murine scleroderma [50] 
LAP
+ Tregs may be a feasible therapeutic approach for treatment of chronic inflammatory diseases like ACS. As CD4
+ LAP + Treg function appears to be compromised in patients with ACS, ACS patients might benefit from this therapeutic strategy. Further studies are warranted to elucidate how to up-regulate the GARP and LAP, thereby raising the frequency of circulating CD4
+ LAP + Tregs in ACS patients. These additional studies are required to comprehensively explore the therapeutic potential of this novel subset of regulatory T cells in coronary heart disease.
